SVP, CFO of BioMarin Pharmaceutical Inc. (BMRN, Financial) Jeffrey H Cooper sells 28,750 shares of BMRN on 10/29/2010 at an average price of $25.32 a share.
Biomarin Pharmaceutical Inc. has a market cap of $2.56 billion; its shares were traded at around $25.6 with a P/E ratio of 227.6 and P/S ratio of 7.9.
BMRN is in the portfolios of Richard Aster Jr of Meridian Fund, Columbia Wanger of Columbia Wanger Asset Management, PRIMECAP Management, RS Investment Management, Bruce Kovner of Caxton Associates, Pioneer Investments, George Soros of Soros Fund Management LLC, Chuck Royce of Royce& Associates.
Biomarin Pharmaceutical Inc. has a market cap of $2.56 billion; its shares were traded at around $25.6 with a P/E ratio of 227.6 and P/S ratio of 7.9.
BMRN is in the portfolios of Richard Aster Jr of Meridian Fund, Columbia Wanger of Columbia Wanger Asset Management, PRIMECAP Management, RS Investment Management, Bruce Kovner of Caxton Associates, Pioneer Investments, George Soros of Soros Fund Management LLC, Chuck Royce of Royce& Associates.
CEO Recent Trades:
- Sell: CEO Jean Jacques Bienaime sold 1,000 shares of BMRN stock on 09/08/2010 at the average price of 22.22. Jean Jacques Bienaime owns at least 95,067 shares after this. The price of the stock has increased by 15.21% since.
- Sell: CEO Jean Jacques Bienaime sold 4,000 shares of BMRN stock on 09/02/2010 at the average price of 20.97. Jean Jacques Bienaime owns at least 95,067 shares after this. The price of the stock has increased by 22.08% since.
- Sell: CEO Jean Jacques Bienaime sold 3,000 shares of BMRN stock on 08/30/2010 at the average price of 20.71. Jean Jacques Bienaime owns at least 99,067 shares after this. The price of the stock has increased by 23.61% since.
- Sell: CEO Jean Jacques Bienaime sold 3,000 shares of BMRN stock on 08/30/2010 at the average price of 20.71. Jean Jacques Bienaime owns at least 99,067 shares after this. The price of the stock has increased by 23.61% since.
- Sell: CEO Jean Jacques Bienaime sold 3,000 shares of BMRN stock on 08/27/2010 at the average price of 20.68. Jean Jacques Bienaime owns at least 99,067 shares after this. The price of the stock has increased by 23.79% since.
CFO Recent Trades:
- Sell: SVP, CFO Jeffrey H Cooper sold 15,209 shares of BMRN stock on 10/25/2010 at the average price of 24. Jeffrey H Cooper owns at least 26,486 shares after this. The price of the stock has increased by 6.67% since.
- Sell: SVP, CFO Jeffrey H Cooper sold 6,000 shares of BMRN stock on 09/13/2010 at the average price of 22.85. Jeffrey H Cooper owns at least 26,486 shares after this. The price of the stock has increased by 12.04% since.
Directors and Officers Recent Trades:
- Sell: VP, Human Resources Mark Wood sold 36,750 shares of BMRN stock on 10/29/2010 at the average price of 26. Mark Wood owns at least 14,243 shares after this. The price of the stock has decreased by 1.54% since.
- Sell: VP, Human Resources Mark Wood sold 937 shares of BMRN stock on 10/22/2010 at the average price of 23.52. Mark Wood owns at least 14,243 shares after this. The price of the stock has increased by 8.84% since.
- Sell: EVP, Chief Medical Officer Henry J Fuchs sold 833 shares of BMRN stock on 10/01/2010 at the average price of 22.3. Henry J Fuchs owns at least 31,000 shares after this. The price of the stock has increased by 14.8% since.
- Sell: VP, Human Resources Mark Wood sold 938 shares of BMRN stock on 09/22/2010 at the average price of 22.92. Mark Wood owns at least 14,243 shares after this. The price of the stock has increased by 11.69% since.
- Sell: EVP, Chief Business Officer Steve Aselage sold 35,000 shares of BMRN stock on 09/08/2010 at the average price of 22. Steve Aselage owns at least 37,587 shares after this. The price of the stock has increased by 16.36% since.
